A vaccine administered during pregnancy is dramatically reducing hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a reduction of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and transferring immunity through the placenta. A significant recent study analysing nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the period when infants are particularly susceptible to the virus. RSV affects roughly 50 per cent of newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.
How the immunisation protects vulnerable infants
RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects approximately half of all newborns in their first few months of life. The virus can range from causing mild cold-like symptoms to triggering severe chest infections that cause babies to struggle to breathe and feed. In the most serious cases, the inflammation in the lungs becomes life-threatening, with small numbers of babies dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of severe RSV infections: “In babies with severe infections you can see their chest and lungs struggling, as they try to pull enough oxygen in. This is very, very frightening as a parent, frightening for good reason.”
The pregnancy vaccine works by stimulating the mother’s immune system to produce defence proteins, which are then transferred to the foetus through the placenta. This maternal immunity offers newborns with instant defence from the point of delivery, exactly when they are most vulnerable to RSV. The new study shows that protection reaches approximately 85% when the vaccine is administered at least four weeks before delivery. Even briefer gaps between vaccination and birth can still deliver substantial defence, with evidence suggesting that a fortnight’s interval is sufficient to shield babies delivered prematurely. Dr Watson recommends pregnant women to have the vaccine at the recommended time, whilst observing that protection remains possible even if administered later in the third trimester.
- Nearly 85% coverage when vaccinated four weeks before birth
- Maternal antibodies transferred through the placenta protect newborns from day one
- Protection possible with 2-week gap before premature birth
- Vaccination during the third trimester still offers significant protection for infants
Compelling evidence from recent research
The efficacy of the RSV vaccine administered during pregnancy has been demonstrated through a thorough investigation carried out throughout England, reviewing data from close to 300,000 babies born between September 2024 and March 2025. This constitutes approximately 90 per cent of all births during that six-month period, providing robust and representative evidence of the vaccine’s real-world impact. The study’s results have been validated by the UK Health Security Agency as showing robust protection for newborns during their most critical early weeks. The breadth of this investigation gives healthcare professionals and parents-to-be with confidence in the vaccine’s demonstrated effectiveness across different groups and contexts.
The results present a compelling picture of the vaccine’s protective effectiveness. More than 4,500 babies were hospitalised with RSV during the study period, with the great majority being infants whose mothers had not received the vaccination. This stark contrast highlights the vaccine’s essential role in preventing serious illness in newborns. The drop in hospital admissions above 80 per cent represents a significant public health achievement, potentially preventing thousands of infants from experiencing the frightening and potentially life-threatening symptoms linked to severe RSV infection. These findings strengthen the importance of the vaccination programme launched in the UK in 2024.
Study methodology and scope
The research analysed birth and hospital admission records from England over a six-month timeframe, capturing data on approximately 90% of all births during this timeframe. By examining around 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were able to establish clear comparisons of RSV infection rates and hospitalisations. The large sample size and thorough nature of the data collection ensured that findings were statistically significant and reflective of the wider population, rather than isolated cases or small subgroups.
The study specifically tracked hospital admissions for RSV among infants born to mothers who had been given the vaccine at different timepoints before delivery. This allowed researchers to establish the shortest interval needed between vaccination and birth for best possible protection, as well as to determine whether protection continued to be effective with briefer timeframes. The methodology captured actual clinical results rather than laboratory-based settings, providing practical evidence of how the vaccine functions when given across different clinical contexts and patient circumstances throughout the final three months of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Understanding RSV and the threats
Respiratory syncytial virus, typically known as RSV, is one of the leading causes of hospital admission in infants aged under twelve months across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their first few months of life, with severity varying dramatically from mild cold-like symptoms to serious, potentially fatal chest infections. Over 20,000 infants require serious hospital treatment for RSV annually in the UK alone, placing enormous strain on paediatric wards and neonatal units during peak seasons.
The infection causes deep inflammation in the lungs and airways, making it dangerously difficult for vulnerable newborns to feed and breathe adequately. Parents commonly see their babies visibly struggling, their chests rising whilst they try to pull enough air into their compromised lungs. Whilst most newborns get better with supportive care, a small but significant number die from RSV-related complications each year, making prevention through vaccination a critical public health imperative for defending the youngest and most vulnerable people in our communities.
- RSV produces lung inflammation, resulting in serious respiratory problems in infants
- Nearly 50% of newborns acquire the infection during their first few months alive
- Symptoms range from minor cold-like symptoms to life-threatening chest infections requiring hospitalisation
- Over 20,000 UK babies require serious hospital care for RSV each year
- A small number of infants succumb to RSV related complications each year in the UK
Adoption rates and specialist advice
Since the RSV vaccine programme launched in 2024, health officials have highlighted the value of pregnant women getting their jab at the ideal time for maximum protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has underscored that timing matters greatly for guaranteeing newborns benefit from the most robust immunity from birth. Whilst the evidence indicates that vaccination at least four weeks before delivery offers approximately 85% protection, experts encourage women to get their vaccine as early as possible from 28 weeks of pregnancy forward to increase the antibodies passed to their babies through the placenta.
The guidance from public health bodies stays clear: pregnant women should make a priority of vaccination during their third trimester, even if circumstances mean they cannot get vaccinated at the optimal time. Dr Watson has reassured expectant mothers that protection remains still achievable with reduced timeframes between vaccination and birth, including even a fourteen-day window for those giving birth ahead of schedule. This adaptable strategy acknowledges the realities of pregnancy and childbirth whilst ensuring strong protection for vulnerable newborns during their earliest and most vulnerable period when RSV poses the greatest risk of serious illness.
Regional variations in vaccine uptake
Whilst the RSV vaccine programme has been implemented across England, uptake rates and deployment schedules have differed across various areas and NHS trusts. Certain regions have achieved greater immunisation rates among eligible pregnant women, whilst others continue working to boost understanding and availability of the jab. These geographical variations reflect variations in healthcare infrastructure, engagement approaches, and local engagement efforts, though the national data demonstrates consistently strong protection regardless of geographical location.
- NHS trusts rolling out multiple messaging strategies to connect with expectant mothers
- Regional disparities in vaccination coverage levels across England require targeted improvement
- Local healthcare systems modifying schemes to align with local requirements and situations
Practical implications and parent viewpoints
The vaccine’s impressive effectiveness translates into tangible benefits for families across the United Kingdom. With more than 20,000 babies admitted to hospital annually due to RSV prior to the rollout of this protective measure, the 80% decrease in admissions means thousands of infants spared from critical disease. Parents no longer face the distressing scenario of watching their newborns gasping for air or difficulty feeding, symptoms that characterise serious RSV disease. The vaccine has substantially transformed the terrain of neonatal respiratory health, giving expectant mothers a active means to safeguard their most at-risk babies during those crucial first weeks.
For families like that of Malachi, whose severe RSV infection caused profound brain damage, the vaccine’s accessibility carries deep personal significance. His mother’s support of the jab underscores the life-altering consequences that vaccine-preventable disease can inflict on young children and their families. Whilst Malachi’s experience comes before the vaccine programme, his story resonates strongly with parents now provided with protection. The knowledge that such serious complications—hospital admission, oxygen dependency, neurological damage—are now largely avoidable has given considerable reassurance to expectant mothers in their third trimester, transforming what was once an predictable seasonal threat into a manageable health risk.